Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study. [electronic resource]
Producer: 20170426Description: 326-334 p. digitalISSN:- 1865-3774
- Aged
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Dexamethasone -- administration & dosage
- Drug Therapy, Combination -- methods
- Female
- Humans
- Lenalidomide
- Leukopenia -- chemically induced
- Lymphopenia -- chemically induced
- Male
- Middle Aged
- Multiple Myeloma -- complications
- Recurrence
- Salvage Therapy -- adverse effects
- Signaling Lymphocytic Activation Molecule Family -- metabolism
- Thalidomide -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article
There are no comments on this title.
Log in to your account to post a comment.